- Company
- Velexbru can be prescribed at general hospitals
- by Eo, Yun-Ho Nov 9, 2023 05:43am
- Velexbru, a new drug for lymphoma, can be prescribed at general hospitals. According to related industries, Ono Pharmaceutical's BTK (Brutons Tyrosine Kinase) inhibitor Velexbru recently passed the Drug Committee of top general hospitals such as AMC and Sinchon Severance Hospital. In addition, major medical institutions, including Samsung Seo
- Company
- Whether Ilaris for 10 will receive reimb gains attention
- by Eo, Yun-Ho Nov 8, 2023 05:37am
- Attention is focused on whether progress will be made on discussions for the insurance reimbursement of 'Ilaris', a treatment that is used by around ten patients in Korea. According to industry sources, reimbursement discussions for Novartis Korea’s Ilaris (canakinumab) are currently being negotiated between the government and pharmaceut
- Company
- Budesonide’s price to be raised due to increased demand
- by Chon, Seung-Hyun Nov 7, 2023 05:34am
- Health authorities are working to increase the price of asthma medications containing ‘budesonide’, which have been experiencing supply shortages. Quarterly prescriptions of budesonide, which was less than KRW 1 billion, more than tripled after the COVID-19 pandemic, intensifying the supply and demand imbalance. According to industry source
- Company
- Chong Kun Dang signs KRW 1.7 tril deal with Novartis
- by Kim, Jin-Gu Nov 7, 2023 05:34am
- On the 6th, Chong Kun Dang Pharm announced on the 6th that it signed a licensing out agreement worth KRW 1.7 trillion for its new drug candidate 'CKD-510' with the global pharmaceutical company Novartis. Under the agreement, Novartis will have exclusive rights to the development and commercialization of CKD Pharm’s CKD-510 worldwide, ex
- Company
- First GIFT drug Lunsumio in reimb process after approval
- by Eo, Yun-Ho Nov 7, 2023 05:33am
- The new lymphoma drug ‘Lunsumio' started the insurance reimbursement process immediately after its approval in Korea. According to industry sources, the anti-CD20/CD3 T-cell engaging bispecific antibody Lunsumio (mosunetuzumab) is starting the listing process using the approval-reimbursement evaluation linkage system. Lunsumio is the
- Company
- Scemblix may be prescribed at Big 5 Hospitals in KOR
- by Eo, Yun-Ho Nov 6, 2023 05:27am
- The next-generation chronic myeloid leukemia drug ‘Scemblix’ can now be prescribed at general hospitals in Korea. According to the industry sources, Novartis Korea's Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) treatment ‘Scemblix (asciminib)' has passed the drug committees of the Big 5 tertiary hospitals in Korea
- Company
- Wegovy and Mounjaro begin to dominate the obesity market
- by Kim, Jin-Gu Nov 6, 2023 05:27am
- Novo Nordisk Wegovy and Eli Lilly Mounjaro have grown explosively in the global market. The two products together generated sales of close to 4 trillion won by the third quarter. In the future, if Mounjaro officially obtains an obesity treatment indication from the FDA, competition between the two products is expected to become more intense.
- Company
- Polivy’s reimb soon to receive CDDC review
- by Eo, Yun-Ho Nov 6, 2023 05:26am
- Whether progress will be made for the reimbursement of the lymphoma treatment ‘Polivy,’ which has applied for reimbursement again after changing its indication to the first-line, is gaining attention. According to industry sources, schedule coordination is underway for the review of the agenda of reimbursing Roche Korea’s Diffuse Large
- Company
- Expansion of coverage for SMA treatment Spinraza
- by Nov 3, 2023 05:32am
- Differentiation between single-dose Zolgensma and oral Evrysdi “Spinraza welcomes relaxation of salary standards” Hyeongjun Park, Professor of Neurology at Gangnam Severance Hospital, gave a presentation on changes in the SMA treatment environment. Biogen's Spinraza, a treatment for spinal muscular atrophy (SMA) with the advantage of dir
- Company
- Cosentyx is approved for hidradenitis suppurativa
- by Eo, Yun-Ho Nov 3, 2023 05:32am
- 'Cosentyx' has entered the field for hidradenitis suppurativa where no other treatment option than ‘Humira’ had been available until now. Moreover, the company plans to immediately enter the market for the indication in Korea as well. According to industry sources, Novartis Korea recently submitted an application to the Ministry of
